Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Anxiety: Overview01:18

Anxiety: Overview

Anxiety is a common mental disorder featuring excessive worry, fear, and apprehension, significantly affecting daily life. People with anxiety disorders experience persistent and intense anxiety, interrupting their everyday functioning.
Individuals with anxiety often experience a range of physical and emotional symptoms, including sweating, trembling, tachycardia, and disturbances in sleep patterns. These symptoms vary in intensity and frequency but are generally disruptive and distressing.
Anxiolytic Drugs: Overview01:26

Anxiolytic Drugs: Overview

Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
Stress and Mental Health01:30

Stress and Mental Health

Chronic stress profoundly affects mental health, significantly influencing mood, behavior, and overall quality of life. Research closely links chronic stress with mental health conditions such as depression, anxiety, and substance use disorders. Ongoing exposure to stress can lead to physiological and psychological changes, initiating a cycle of emotional distress and maladaptive coping mechanisms.
Individuals with depression often experience challenges in both their personal and professional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GlyT1 inhibition enhances working memory in the mouse TUNL task and normalizes NMDA antagonist-induced network activity.

Psychopharmacology·2026
Same author

Effort, timing and choice: a refined rodent effort choice task with excellent sensitivity to dopamine modulators.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Discovery of VU6053371/BI03738809: A First-in-Class Selective and CNS-Penetrant mGlu<sub>3</sub> Positive Allosteric Modulator (PAM) with Efficacy in a Preclinical Cognition Model.

ACS chemical neuroscience·2026
Same author

Editorial: Sixty years from THC: Landscape and perspectives on the pharmacology of cannabinoids.

Pharmacological research·2026
Same author

Targeting the Kynurenine Pathway to Improve Mood Disorders.

Current neuropharmacology·2026
Same author

Differential modulation of contextual fear conditioning by orexin receptors in the dorsal hippocampus.

Behavioural brain research·2025
Same journal

Classifying Psychedelic-Related Complications.

Current topics in behavioral neurosciences·2026
Same journal

Psychedelic-Related Psychosis: From Model Psychosis to Psychotherapy.

Current topics in behavioral neurosciences·2026
Same journal

Managing Psychological Challenges in the Subacute ("Afterglow") Window of Psychedelic Drug Effects.

Current topics in behavioral neurosciences·2025
Same journal

Flashbacks, Hallucinogen Persisting Perception Disorder (HPPD), and Reactivations Following the Use of Classic Psychedelics: Classification and Therapeutic Management.

Current topics in behavioral neurosciences·2025
Same journal

Correction to: Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics.

Current topics in behavioral neurosciences·2025
Same journal

Ontologically Challenging Psychedelic Experiences: Considerations for Managing Associated Distress.

Current topics in behavioral neurosciences·2025
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements
05:42

Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements

Published on: January 7, 2019

Cannabinoids and anxiety.

Fabrício A Moreira1, Carsten T Wotjak

  • 1Department of Pharmacology, Federal University of Minas Gerais, Av. António Carlos 6627, Belo Horizonte, MG 31270-901, Brazil.

Current Topics in Behavioral Neurosciences
|February 11, 2011
PubMed
Summary
This summary is machine-generated.

Cannabinoids, acting on cannabinoid type 1 (CB1) receptors, influence anxiety and fear. Modulating the endocannabinoid system offers potential for developing new anxiolytic drugs.

More Related Videos

Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

Social Isolation Model: A Noninvasive Rodent Model of Stress and Anxiety
04:20

Social Isolation Model: A Noninvasive Rodent Model of Stress and Anxiety

Published on: November 11, 2022

Related Experiment Videos

Last Updated: Jun 4, 2026

Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements
05:42

Elevated Plus Maze Test Combined with Video Tracking Software to Investigate the Anxiolytic Effect of Exogenous Ketogenic Supplements

Published on: January 7, 2019

Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

Social Isolation Model: A Noninvasive Rodent Model of Stress and Anxiety
04:20

Social Isolation Model: A Noninvasive Rodent Model of Stress and Anxiety

Published on: November 11, 2022

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Cannabinoids, including plant-derived and synthetic compounds, primarily act via cannabinoid type 1 (CB1) receptors.
  • The endocannabinoid system comprises CB1 receptors, endogenous ligands (endocannabinoids like anandamide and 2-AG), and their metabolizing enzymes.

Purpose of the Study:

  • To summarize current knowledge on the role of cannabinoids and endocannabinoids in fear and anxiety.
  • To explore the potential of the endocannabinoid system as a therapeutic target for anxiolytic drugs.

Main Methods:

  • Review of existing research on cannabinoid and endocannabinoid effects on anxiety- and fear-related behaviors.
  • Analysis of the impact of modulating endocannabinoid degradation and CB1 receptor activity.
  • Consideration of the role of Transient Receptor Potential Vanilloid Type-1 (TRPV1) channels.

Main Results:

  • Cannabinoids exhibit biphasic effects on anxiety, with low doses being anxiolytic and high doses anxiogenic.
  • Inhibiting endocannabinoid degradation enhances CB1 signaling, reducing anxiety-like behaviors.
  • CB1 receptor blockade or deletion leads to anxiogenic effects and impaired extinction of aversive memories.
  • Pharmacological blockade of TRPV1 channels produces opposite effects to CB1 modulation.

Conclusions:

  • The endocannabinoid system plays a significant role in regulating fear and anxiety.
  • Targeting the endocannabinoid system, particularly through modulation of endocannabinoid degradation, shows promise for developing novel anxiolytic treatments.